



HAL
open science

Biological roles of anti-GM1 antibodies in patients with Guillain-Barré syndrome for nerve growth factor signaling

Toshifumi Tanaka, Daisuke Furutama, Reiko Sakai, Atsushi Fujita, Fumiharu Kimura, Muneyoshi Tagami, Nakaaki Ohsawa, Toshiaki Hanafusa

► To cite this version:

Toshifumi Tanaka, Daisuke Furutama, Reiko Sakai, Atsushi Fujita, Fumiharu Kimura, et al.. Biological roles of anti-GM1 antibodies in patients with Guillain-Barré syndrome for nerve growth factor signaling. *Biochimica et Biophysica Acta - Molecular Basis of Disease*, 2007, 1772 (5), pp.543. <10.1016/j.bbadis.2007.01.011>. <hal-00562763>

HAL Id: hal-00562763

<https://hal.science/hal-00562763v1>

Submitted on 4 Feb 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

Accepted Manuscript


Biological roles of anti-GM1 antibodies in patients with Guillain-Barré syndrome for nerve growth factor signaling

Toshifumi Tanaka, Daisuke Furutama, Reiko Sakai, Atsushi Fujita, Fumiharu Kimura, Muneyoshi Tagami, Nakaaki Ohsawa, Toshiaki Hanafusa

PII: S0925-4439(07)00034-8
DOI: doi: [10.1016/j.bbadis.2007.01.011](https://doi.org/10.1016/j.bbadis.2007.01.011)
Reference: BBADIS 62690

To appear in: *BBA - Molecular Basis of Disease*

Received date: 5 September 2006
Revised date: 28 December 2006
Accepted date: 23 January 2007



Please cite this article as: Toshifumi Tanaka, Daisuke Furutama, Reiko Sakai, Atsushi Fujita, Fumiharu Kimura, Muneyoshi Tagami, Nakaaki Ohsawa, Toshiaki Hanafusa, Biological roles of anti-GM1 antibodies in patients with Guillain-Barré syndrome for nerve growth factor signaling, *BBA - Molecular Basis of Disease* (2007), doi: [10.1016/j.bbadis.2007.01.011](https://doi.org/10.1016/j.bbadis.2007.01.011)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Biological roles of anti -GM1 antibodies in patients with Guillain-Barré syndrome for nerve growth factor signaling.

Toshifumi Tanaka^{1,2,3}, Daisuke Furutama^{1,3}, Reiko Sakai^{1,2}, Atsushi Fujita^{1,3}, Fumiharu Kimura³, Muneyoshi Tagami³, Nakaaki Ohsawa¹, Toshiaki Hanafusa³

¹Aino Institute for Aging Research, Osaka, Japan

²Department of Nursing, Aino Gakuin College

³First Department of Internal Medicine, Osaka Medical College

All correspondence should be addressed to:

Daisuke Furutama, M.D.

Aino Institute for Aging Research, Oda 27, Ibaraki-city, Osaka, 567-0018, Japan

Phone: +81-726-21-3745

Fax: +81-726-27-7878

E-mail: in1003@poh.osakamed.ac.jp

Key words : Guillain-Barré syndrome, anti-GM1 antibodies, Trk A, Nerve growth factor

This manuscript contains 29 references, 6 figures and 2 tables.

Word count: Title 15 words, Abstract 177 words, and Text 1601 words

Summary

To reveal the biological and pathological roles of anti-GM1 antibody in Guillain-Barré syndrome (GBS), we examined its effects on nerve growth factor (NGF) induced TrkA autophosphorylation (NGF-TrkA signaling) in PC12 cells, a sympathetic nerve cell line. The NGF-TrkA signaling is enhanced by exogenous GM1 ganglioside and this phenomenon is regarded as one of the functional aspects of GM1. The IgGs purified from patients' sera inhibited the NGF-TrkA signaling in GM1 pre-incubated PC12 cells. The degrees of inhibition by IgGs from patients paralleled their immunological reactivity to GM1. In addition, the IgGs also inhibited the neurite outgrowth of NGF-treated PC12 cells. Immunoglobulins in the rabbit sera, which were immunized by GM1, also caused a similar suppressive phenomenon. These results suggested that the anti-GM1 antibody could play roles in pathophysiology in anti-GM1 antibody positive GBS through interfering with the neurotrophic action of NGF and GM1 mediated signal modulation including NGF-TrkA signaling. It is suggested that the modulation of GM1 function is one important action of antibodies and could be one of the important mechanisms in GBS.

1. Introduction

In Guillain-Barré syndrome (GBS) and its variants there are miscellaneous antibodies against certain gangliosides. The kind of the antibody is closely related to the disease type and removal of these antibodies by plasmapheresis is an effective treatment to improve the diseases. Therefore these antibodies have been postulated as effector molecules in these peripheral neuropathies. Particularly IgG class anti monosialogangliosides GM1 (GM1) antibodies have been implicated as potential pathogenic agents[1-3]. However the roles of these antibodies in the pathophysiology of GBS and molecular mechanisms to impair the nerve tissues are still unclear.

Recently GM1 has been known as not only a structural molecule but a functional molecule, i.e., modifier of signal transduction.[4] For example exogenous GM1 enhances the autophosphorylation of TrkA, a specific nerve growth factor (NGF) receptor, induced by NGF (NGF-TrkA signaling) and augments the neurite outgrowth in PC12 cells, a sympathetic nerve cell line. [5-7] However, little attention has been paid to the functional aspects of GM1 in the studies of GBS pathogenesis.

In this study, we adopted the potentiating effect of GM1 to NGF-TrkA signaling on PC12 cells[5-7] as the assay system for testing the biological activity of anti-GM1 antibodies, and tried to reveal the mechanisms of GBS pathogenesis caused by the anti-GM1 antibody.

2. Materials and Methods

2.1. Isolation of immunoglobulin.

Sera obtained from four GBS patients in the acute phase before plasmapheresis (Table 1) and four age-matched normal volunteers were tested for reactivity to GM1[4] and *Campylobacter jejuni* by ELISA[8]. The IgG immunoglobulins were isolated from these sera using Protein-L (Nab™ Protein-L Spin Chromatography kit, Pierce) and the samples were adjusted to 1 mg/ml concentration and stored at -20°C. In some experiments, IgG immunoglobulins were used, from which anti-GM1 antibodies were depleted with the GM1 immobilized plate.

2.2. Cell cultures.

PC12 cells (Human Science Research Resource Bank, Osaka) were maintained in RPMI medium (RPMI1640, GIBCO BRL) supplemented with 10% heat-inactivated horse serum and 5% fetal bovine serum. To detect phosphorylated proteins, cells were cultured on a collagen-coated 12-well plate for one day, and then cultured in serum-free RPMI medium, when indicated, with 50 µM GM1 (Sigma) for 12 hrs at 37°C. After exposure to GM1, cells were washed by serum-free RPMI medium and preincubated with immunoglobulin isolated from patients' or control serum, or rabbit anti-GM1 IgG (Calbiochem) at the indicated concentration (25 - 100 µg/ml) for 30 minutes at 37°C. Then cells were treated with NGF (7S NGF, Sigma) at 50 ng/ml for 30 minutes. [5] For morphological studies, the cells were cultured on 6-well plates at 5×10⁴ cells/well and treated with GM1, immunoglobulins and NGF in the same conditions described above.

After an additional 72 hrs of culturing ten different microscope fields were selected blindly, photographs taken, and the neurite outgrowth was quantitated by comparing the neurite length and the somal diameter. The neurite index was calculated as the ratio of the number of cells with neurites (longer than $2 \times$ somal diameter) to those without neurites.[4]

2.3. Immunoprecipitation and Immunoblotting

After NGF treatment, the cells were immediately washed by ice-cold PBS with 1 mM Na_3VO_4 and lysed in lyses buffer (20 mM Tris-HCl, pH 8.0/ 137 mM NaCl/ 1% NP-40/ 10% glycerol/ 50 mM NaF/ 1 mM Na_3VO_4 / 1 mM PMSF/ 1 $\mu\text{g}/\text{ml}$ leupeptine/ 10 $\mu\text{g}/\text{ml}$ aprotinin) for 30 minutes on ice with agitation. High-speed centrifuge (10,000g) was performed to obtain cell free lysate and the lysates were normalized for proteins. To detect TrkA phosphorylation, the cell-free lysates were immunoprecipitated with anti-TrkA antibody agarose conjugated (Santa-Cruz) at 4°C over night. The resultant immunoprecipitates were electrophoretically transferred to PVDF membranes after SDS-PAGE with 8% gels and were probed with anti-phosphotyrosine antibody (PY20, Zymed Laboratories Inc). Detection was performed according to the manufacture's direction (ECL plus, Amersham). The membrane was reprobbed with anti-TrkA monoclonal antibody (Santa-Cruz) using manufacturer-specified reprobing protocols (ECL manual, Amersham).[5-7] To quantify the signals on the films, densitometry was performed on personal computer using NIH Image and the ratio of the phosphorylated proteins (p-TrkA) to the total amount of the proteins (total TrkA) was calculated.

3. Results

3.1. Clinical and Immunological profiles of the patients (Table1, Table2).

All four patients had diarrhea before the onset of GBS symptoms and three patients showed positive anti-*Campylobacter jejuni* antibodies. They showed grade 3 to 5 severity (Hughes functional grade [9]) and were electrophysiologically diagnosed as acute motor axonal neuropathy (AMAN) on the grounds that they showed fibrillation voltage in electromyography and a decrease of compound muscle action potential with normal conduction velocity. All patients had IgG type anti-GM1 antibodies.

3.2. Effects of GM1 incorporation on TrkA phosphorylation.

It is reported that exogenous GM1 enhances TrkA autophosphorylation caused by NGF.[5-7] To confirm this phenomenon in our experimental system, we examined the effects of GM1 incorporation, 50 μ M for 12 hrs, on TrkA phosphorylation in PC12 cells. We observed about a 2-fold increase in NGF-induced TrkA autophosphorylation in GM1-treated PC12 cells compared with that in GM1-untreated cells (Fig. 1).

3.3. Influence of GM1-immunized rabbits' sera and immunoglobulins derived from normal controls and patients with GBS on NGF-TrkA signaling.

To ascertain that anti-GM1 antibody inhibits the potentiating effects of GM1 on NGF-TrkA signaling we performed examinations using sera from GM1-immunized rabbits. It suppressed the exogenous GM1 enhanced NGF-TrkA signaling on GM1-treated PC12 cells with dose dependency (Fig. 2A-C) and GM1 non-immunized

rabbit's sera didn't show such depressive effects (Fig.2D).

Immunoglobulins from the four normal controls that did not react to GM1 (Table. 2) showed no effects on the TrkA autophosphorylation (Fig. 3). Immunoglobulins derived from GBS patients inhibited the TrkA autophosphorylation dose-dependently (25 to 100 $\mu\text{g/ml}$) (Fig. 4) and proportionally to their reactivity to GM1 (Table. 2 and Fig. 5A-C). The anti-GM1 antibody-depleted immunoglobulins could no longer depress the TrkA autophosphorylation (Fig. 5D).

3.4. Effects of immunoglobulins on NGF induced neurite outgrowth.

Photomicrographs of GM1-incorporated PC12 cells treated with or without NGF and immunoglobulins are shown in Fig. 6. There is no neurite formation in the absence of NGF (Fig. 6A-D). NGF-induced neurite outgrowth is arrested by the addition of immunoglobulins only from GBS patients (Fig. 6E-H). The neurite index indicates the almost complete inhibition of NGF-induced neurite outgrowth by patients' immunoglobulins (Fig. 6E-H).

4. Discussion

In this paper we showed that the GBS (AMAN) patients' IgG, which was reactive to GM1, inhibited the potentiating effect of GM1 to NGF-TrkA signaling dose-dependently and interfered with the NGF induced neurite outgrowth in PC12 cells. It is reasonable to suppose that this inhibition was due to the IgG reacting directly to GM1, because sera from rabbits immunized by GM1 had similar suppressing effects with dose-dependency (Fig 2), the degree of the inhibition was in proportion to the reactivity to GM1 of incubated IgG (Fig. 4), and the anti-GM1 antibody-absorbed immunoglobulins didn't have such depressive effects. On the other hand, O'Hanlon et al. reported that monoclonal anti-GM1 IgM antibody from human neuropathy induced small neuritogenic effects on PC12 cells[10]. Although it appears to conflict with our results, this difference may arise from the difference between IgG and IgM, in that anti-GM1 IgM antibody relates to multifocal motor neuropathy rather than to AMAN. These results suggested that the interaction between GM1 on plasma membranes and anti-GM1 antibodies affected the *in vivo* nervous system in the patients with anti-GM1-antibody-positive GBS, particularly with AMAN in which mainly affected on the axon of neuron, since the PC12 cell is not a model of Schwann cell but nerve cell.

Ten to 42% of patients with GBS have high titer of anti-GM1 antibody[11-13] and it has been suggested that IgG antibodies against GM1 were strongly associated both with axonal degeneration and reversible conduction failure in GBS[14, 15]. The effects of anti-GM1 antibodies on the electrical activity of nerve tissues have been reported and it was suggested that the antibodies could cause damages to neural

membranes or interfere with nerve conduction, or both [16-19]. Nevertheless it is still difficult to explain, for example, why there are many autoantibody-negative patients, or why damage to the nerve conduction is reversible. These facts suggest that we have to consider another functional aspect of anti-GM1 antibody in GBS pathogenesis. Our results indicated the functional significance of anti-GM1 antibody, which is the interference with the biological function of GM1.

In some peripheral neuropathies neurotrophic factors and their receptors' expression increased at peripheral nerve tissue [20, 21]. Nerve growth factors have various effects on neuronal cells including regeneration and survival. Although their pathophysiological roles in GBS were unclear, the fact of increased expression suggests their functional significance in GBS pathophysiology. For example, it is well known that NGF plays important roles in nerve regeneration and repair. In addition, anti-GM1 antibodies and its subclass pattern were tightly related to the slow recovery of GBS [22]. Owing to these facts, our results suggested the association between the blocking of neurotrophic factor signaling by anti-GM1 antibodies and the prolonged recovery of GBS.

GM1 has been implicated in neuronal development and differentiation [23]. Exogenous gangliosides promote neurite outgrowth in primary cultures of neuron and cell lines, and facilitate the repair of damaged neuronal cells. It was suggested that the exogenous ganglioside exert these effects by modulation of the function of growth factor receptors [6, 7, 24-26]. Therefore gangliosides could be understood as signaling modulators for some types of receptors [27]. Mutoh et al. have shown that the

exogenously added GM1 gets tightly associated with TrkA receptor protein and enhances the autophosphorylation of the receptor [5]. It is still unclear how GM1 enhances the NGF-TrkA signaling but it is suggested that GM1 must be membrane bound to be effective, that is incorporated into the cell membrane [27, 28]. Recently GM1 has been known as one of the structural and functional molecules in the micro domain of the cell membrane, the so-called “functional lipid raft” especially in immune cells [29, 30]. PC12 cells also have this micro domain which contain TrkA [31]. Using confocal microscopy, we observed that anti-GM1 antibodies caused the aggregation of GM1 on the cell membrane of PC12 cells (preliminary unpublished observation). It can be speculated that anti-GM1 antibodies interfere with the NGF-TrkA signaling by functional modification of the micro domain. If this speculation is true, anti-GM1 antibody could affect other signal transduction not only in neural cells but also in immune cells, for example brain derived nerve growth factor (BDNF) signaling in motor neurons and T cell receptor signaling in lymphocytes. These modulations could contribute to the immunological pathophysiology in GBS.

In conclusion, the anti-GM1 antibody may have effects on the pathophysiology in anti-GM1-antibody-positive GBS through disturbing neurotrophic action. It is important to regard the antibody as a modifier to GM1 function and, from this point of view, further investigation is needed to elucidate the role of the “GM1-anti-GM1 interaction” for understanding the GBS pathogenesis.

References

- [1] R.H. Quarles and M.D. Weiss, Autoantibodies associated with peripheral neuropathy, *Muscle Nerve* 22 (1999) 800-22.
- [2] N. Yuki, H. Yoshino, S. Sato and T. Miyatake, Acute axonal polyneuropathy associated with anti-GM1 antibodies following *Campylobacter* enteritis, *Neurology* 40 (1990) 1900-2.
- [3] B.C. Jacobs, P.A. van Doorn, P.I. Schmitz, A.P. Tio-Gillen, P. Herbrink, L.H. Visser, H. Hooijkass and F.G. van der Meche, *Campylobacter jejuni* infections and anti-GM1 antibodies in Guillain - Barré syndrome, *Ann Neurol* 40 (1996) 181-7.
- [4] B. Ravichandra and P.G. Joshi, Regulation of transmembrane signaling by ganglioside GM1: interaction of anti-GM1 with Neuro2a cells, *J Neurochem* 73 (1999) 557-67.
- [5] T. Mutoh, A. Tokuda, T. Miyadai, M. Hamaguchi and N. Fujiki, Ganglioside GM1 binds to the Trk protein and regulates receptor function, *Proc Natl Acad Sci U S A* 92 (1995) 5087-91.
- [6] S.J. Rabin and I. Mochetti, GM1 ganglioside activates the high-affinity nerve growth factor receptor trkA, *J Neurochem* 65 (1995) 347-54.
- [7] T. Farooqui, T. Franklin, D.K. Pearl and A.J. Yates, Ganglioside GM1 enhances induction by nerve growth factor of a putative dimer of TrkA, *J Neurochem* 68 (1997) 2348-55.

- [8] F. Kimura, T. Ito, N. Yuki, H. Nakajima, T. Tanaka, K. Shinoda and N. Ohsawa, Longitudinal study of serum and cerebrospinal fluid (CSF) class-specific antibodies against *Campylobacter jejuni* and GM1 ganglioside in Guillain - Barré syndrome., *Intern Med.* 34 (1995) 1009-14.
- [9] R.A. Hughes, J.M. Newsom-Davis, G.D. Perkin and J.M. Pierce, Controlled trial prednisolone in acute polyneuropathy, *Lancet* 2 (1978) 750-3.
- [10] G.M. O'Hanlon, T.R. Hirst and H.J. Willison, Ganglioside GM1 binding toxins and human neuropathy-associated IgM antibodies differentially promote neuritogenesis in a PC12 assay, *Neurosci Res* 47 (2003) 383-90.
- [11] J.H. Rees, N.A. Gregson and R.A. Hughes, Anti-ganglioside GM1 antibodies in Guillain - Barré syndrome and their relationship to *Campylobacter jejuni* infection, *Ann Neurol* 38 (1995) 809-16.
- [12] T.W. Ho, B. Mishu, C.Y. Li, C.Y. Gao, D.R. Cornblath, J.W. Griffin, A.K. Asbury, M.J. Blaser and G.M. McKhann, Guillain - Barré syndrome in northern China. Relationship to *Campylobacter jejuni* infection and anti-glycolipid antibodies, *Brain* 118 (Pt 3) (1995) 597-605.
- [13] F.J. Vriesendorp, W.J. Triggs, R.F. Mayer and C.L. Koski, Electrophysiological studies in Guillain- Barré syndrome: correlation with antibodies to GM1, GD1B and *Campylobacter jejuni*, *J Neurol* 242 (1995) 460-5.
- [14] S. Kuwabara, N. Yuki, M. Koga, T. Hattori, D. Matsuura, M. Miyake and M. Noda, IgG anti-GM1 antibody is associated with reversible conduction failure

- and axonal degeneration in Guillain - Barré syndrome, *Ann Neurol* 44 (1998) 202-8.
- [15] K. Ogawara, S. Kuwabara, M. Mori, T. Hattori, M. Koga and N. Yuki, Axonal Guillain - Barré syndrome: relation to anti-ganglioside antibodies and *Campylobacter jejuni* infection in Japan, *Ann Neurol* 48 (2000) 624-31.
- [16] Dilley A, Gregson NA, Hadden RD and Smith KJ, Effects on axonal conduction of anti-ganglioside sera and sera from patients with Guillain - Barré syndrome., *J Neuroimmunol.* 139 (2003) 133-40.
- [17] K. Arasaki, S. Kusunoki, N. Kudo and I. Kanazawa, Acute conduction block in vitro following exposure to antiganglioside sera, *Muscle Nerve* 16 (1993) 587-93.
- [18] N. Hirota, R. Kaji, H. Bostock, K. Shindo, T. Kawasaki, K. Mizutani, N. Oka, N. Kohara, T. Saida and J. Kimura, The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons, *Brain* 120 (Pt 12) (1997) 2159-69.
- [19] T. Takigawa, H. Yasuda, R. Kikkawa, Y. Shigeta, T. Saida and H. Kitasato, Antibodies against GM1 ganglioside affect K⁺ and Na⁺ currents in isolated rat myelinated nerve fibers, *Ann Neurol* 37 (1995) 436-42.
- [20] Yamamoto M, Ito Y, Mitsuma N, Li M, Hattori N and Sobue G, Parallel expression of neurotrophic factors and their receptors in chronic inflammatory demyelinating polyneuropathy, *Muscle Nerve* 25 (2002) 601-604.
- [21] G. Sobue, T. Yasuda, T. Mitsuma, A. Ross and D. Pleasure, Expression of

- nerve growth factor receptor in human peripheral neuropathies, *Ann Neurol* 24 (1988) 64-72.
- [22] M. Koga, N. Yuki, K. Hirata, M. Morimatsu, M. Mori and S. Kuwabara, Anti-GM1 antibody IgG subclass: a clinical recovery predictor in Guillain-Barré syndrome., *Neurology* 60 (2003) 1514-8.
- [23] Leon A, Facci L, Benvegnu D and Toffano G, Morphological and biological effects of gangliosides in neuroblastoma cells, *Dev. Neurosci* 5 (1982) 108-114.
- [24] Ferrari G, Fabris M and Gorio A, Ganglioside enhance neurite outgrowth in PC12 cells, *Dev Brain Res* 8 (1983) 215-221.
- [25] Ferrari G, Anderson BL, Stephens RM, Kaplan DR and Greene LA, Prevention of apoptotic neuronal death by GM1 ganglioside. Involvement of Trk neurotrophin receptors, *J Biol Chem* 270 (1995) 3074-3080.
- [26] Meuillet E, Cremel G, Dreyfus H and Hicks D, Differential modulation of basic fibroblast and epidermal growth factor receptor activation by ganglioside GM3 in cultured retinal Muller glia, *Glia* 17 (1996) 206-216.
- [27] A.J. Yates and A. Rampersaud, Sphingolipids as receptor modulators. An overview, *Ann N Y Acad Sci* 845 (1998) 57-71.
- [28] Saqr HE, Pearl DK and Yates AJ, A review and predictive models of ganglioside uptake by biological membranes, *J Neurochem* 61 (1993) 395-411.
- [29] T.O. Nashar, Z.E. Betteridge and R.N. Mitchell, Antigen binding to GM1 ganglioside results in delayed presentation: minimal effects of GM1 on

presentation of antigens internalized via other pathways, *Immunology* 106 (2002) 60-70.

[30] K. Simons and E. Ikonen, Functional rafts in cell membranes, *Nature* 387 (1997) 569-72.

[31] S. Peiro, J.X. Comella, C. Enrich, D. Martin-Zanca and N. Rocamora, PC12 cells have caveolae that contain TrkA. Caveolae-disrupting drugs inhibit nerve growth factor-induced, but not epidermal growth factor-induced, MAPK phosphorylation, *J Biol Chem* 275 (2000) 37846-52.

Table 1 Clinical features of GBS patients

| No. | Age | Sex | Diarrhea | Cranial nerve | Severity* | Recovery** | Electrophysiological Diagnosis |
|-----|-----|-----|----------|------------------|-----------|------------|-----------------------------------|
| #1 | 52 | F | + | - | 4 | 4 | AMAN |
| #2 | 24 | M | + | - | 4 | 2.5 | AMAN |
| #3 | 45 | M | + | - | 3 | 2 | AMAN |
| #4 | 26 | M | + | - | 5 | 36< | AMAN |

*: Hughes functional grade[9] at the peak, **: months until able to walk independently

(Grade 2) from onset, AMAN: Acute motor axonal neuropathy

Table 2 Relative reactivities of sera from patients and controls against the GM1.

| | GM1 ganglioside | | |
|----------|-----------------|-----|-----|
| | IgG | IgM | IgA |
| patients | | | |
| #1 | + | + | + |
| #2 | + | ++ | + |
| #3 | ++ | + | - |
| #4 | +++ | - | - |
| controls | | | |
| #1 | - | - | - |
| #2 | - | - | - |
| #3 | - | - | - |
| #4 | - | - | - |

(-), (+), (++) and (+++) mean <x160, x160, x320, x640 respectively against the indicated antigens using ELISA. Cut-off value is an average of healthy control [8].

Figure legends**Fig. 1. Effects of GM1 incorporation to the NGF-TrkA signaling.**

A. TrkA phosphorylation was assessed by immunoblot analysis using anti-phospho-tyrosine antibody. Arrowheads indicate TrkA. B. Total TrkA levels were determined using anti-Total TrkA antibody. C. The ratio of phosphorylated TrkA to total TrkA were normalized to net intensity values for GM1 untreated controls and represented the mean with S.E. (error bar) of three replicate experiments. The asterisk shows significant ($P < 0.05$) difference between indicated data pair.

Fig. 2. Effects of antibody from GM1-immunized rabbit to the NGF-TrkA signaling on GM1-incorporated PC12 cells.

A. TrkA phosphorylation was assessed by immunoblot analysis using anti-phospho-tyrosine antibody. Arrowheads indicate TrkA. B. Total TrkA levels were determined using anti-Total TrkA antibody. C. The ratio of phosphorylated TrkA to total TrkA were normalized to net intensity values for NGF treated without the antibody controls and represented the mean with S.E. (error bar) of three replicate experiments. The asterisks show significant ($P < 0.05$) differences between indicated data pairs. D. The ratio of phosphorylated TrkA to total TrkA. Cells were treated by 50 ng/ml NGF without rabbit's serum (1), with serum from GM1 immunized rabbit (2) and with serum from unimmunized rabbit (3).

Fig. 3. Effects of IgG isolated from normal controls to the NGF-TrkA signaling on GM1 incorporated PC12 cells.

A. TrkA phosphorylation was assessed by immunoblot analysis using anti-phospho-tyrosine antibody. Arrowheads indicate TrkA. B. Total TrkA levels were determined using anti-Total TrkA antibody. C. The ratio of phosphorylated TrkA to total TrkA were normalized to net intensity values for NGF treated without the antibody controls and represented the mean with S.E. (error bar) of three replicate experiments. There were no significant differences between each data pairs.

Fig. 4. Dose dependency of the IgG isolated from GBS patients to the NGF-TrkA signaling on GM1-incorporated PC12 cells.

Cells were stimulated by 50 ng/ml NGF. A. TrkA phosphorylation was assessed by immunoblot analysis using anti-phospho-tyrosine antibody. Arrowheads indicate TrkA. B. Total TrkA levels were determined using anti-Total TrkA antibody. C. The ratio of phosphorylated TrkA to total TrkA were normalized to net intensity values for the antibody untreated controls and represented the mean with S.E. (error bar) of three replicate experiments. The asterisks show significant ($P < 0.05$) differences between indicated data pairs.

Fig. 5. Effects of IgG isolated from GBS patients and a control to the NGF-TrkA

signaling on GM1 incorporated PC12 cells.

Cells were stimulated by 50 ng/ml NGF. A. TrkA phosphorylation was assessed by immunoblot analysis using anti-phosphotyrosine antibody. Arrowheads indicate TrkA. B. Total TrkA levels were determined using anti-Total TrkA antibody. C. The ratio of phosphorylated TrkA to total TrkA were normalized to net intensity values for the antibodies untreated controls and represented the mean with S.E. (error bar) of three replicate experiments. There are significant ($P < 0.05$) differences between all data pairs without indicated by N.S. D. The ratio of phosphorylated TrkA to total TrkA. The black/white bars indicate the ratios obtained from GBS patient's immunoglobulin before/after treatment by GM1 absorption column. 1: Control #1, 2: Patient #4, 3: Patient #3, 4: Patient #1.

Fig. 6. Morphological examinations of neurite outgrowth of GM1-incorporated PC12 cells at 72 hours after NGF stimulation.

A-D. NGF (-), E-H. 50 ng/ml NGF, A and E: IgG (-), B and F: 100 μ g/ml IgG (control), C and G: 100 μ g/ml IgG (patient #2), D and H 100 μ g/ml IgG (patient #4). The neurite index was shown (see *materials and methods*).

